HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RGNX
REGENXBIO Inc.
RGNX lost money over the past year, so it has no meaningful PE right now.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RGNX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Strong |
RGNX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RGNX PE Valuation
RGNX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RGNX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.21 | +$0.24 |
| Q2 2026 | -$3.79 | -$0.37 |
| Q1 2026 | -$5.60 | -$2.51 |
| Q4 2025 | -$3.76 | +$0.83 |
| Q3 2025 | -$3.45 | +$1.57 |
| Q2 2025 | -$3.42 | +$1.84 |
| Q1 2025 | -$3.09 | +$2.78 |
| Q4 2024 | -$4.59 | +$1.43 |
RGNX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RGNX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RGNX on profitability, with a higher operating margin.
RGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.2M | -69% |
| Q2 2026 | $108M | +406% |
| Q1 2026 | $6.4M | -93% |
| Q4 2025 | $30.3M | +43% |
| Q3 2025 | $29.7M | +23% |
| Q2 2025 | $21.4M | -4.2% |
| Q1 2025 | $89M | +470% |
| Q4 2024 | $21.2M | -4.5% |
RGNX's revenue has slid since its 2021 peak: $9M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -388% | -212 points |
| Q2 2026 | 27% | +323 points |
| Q1 2026 | -1304% | -1318 points |
| Q4 2025 | -190% | +52 points |
| Q3 2025 | -176% | +80 points |
| Q2 2025 | -296% | -45 points |
| Q1 2025 | 14% | +422 points |
| Q4 2024 | -242% | +46 points |
RGNX's operating margin was −388% last quarter, down 212 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RGNX on cash generation, producing positive trailing cash flow while its opponent burns cash.
RGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +$94.9M |
| Q2 2026 | -$63M | -$13.3M |
| Q1 2026 | -$77.4M | -337% |
| Q4 2025 | -$52.8M | -$20.1M |
| Q3 2025 | -$56.5M | -$15.6M |
| Q2 2025 | -$49.7M | -$3.8M |
| Q1 2025 | $32.6M | +$88.6M |
| Q4 2024 | -$32.7M | +$9.2M |
RGNX has burned cash in almost every quarter: −$155M over the past year, against −$106M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RGNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +23% | +12.2M shares |
| 1 year | +26% | +13.6M shares |
| 3 years | +51% | +22.1M shares |
| 5 years | +76% | +28.2M shares |
RGNX has 65M diluted shares, up 26% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RGNX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -1.0x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -1.3x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
RGNX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 20.6 | Neutral |
RGNX's weekly RSI is 47 (neutral) and its Stochastic is 21 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RGNX PE vs Healthcare Sector
| Metric | RGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGNX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.42 | 8.2% above |
| 20 week MA | $9.16 | 12% below |
| 50 week MA | $9.59 | 16% below |
| 100 week MA | $9.22 | 13% below |
| 200 week MA | $12.9 | 38% below |
RGNX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over RGNX on returns for 2026, with the stronger performance.
RGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $48.7 | +20% |
| 2021 | $48.7 | $34.8 | -29% |
| 2022 | $34.8 | $22.3 | -36% |
| 2023 | $22.3 | $18.0 | -19% |
| 2024 | $18.0 | $7.41 | -59% |
| 2025 | $7.41 | $14.2 | +91% |
| 2026 YTD | $14.2 | $8.03 | -43% |
RGNX has finished lower in four of the last six years. It's down 43% so far in 2026.